Torsdag 31 Oktober | 11:07:53 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2025-02-20 07:00 Bokslutskommuniké 2024
2024-11-11 07:00 Kvartalsrapport 2024-Q3
2024-10-11 - 15-6 2024
2024-09-30 - Extra Bolagsstämma 2024
2024-08-13 - Kvartalsrapport 2024-Q2
2024-06-17 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-05-14 - X-dag ordinarie utdelning CALTX 0.00 SEK
2024-05-13 - Årsstämma
2024-02-21 - Bokslutskommuniké 2023
2023-11-07 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-30 - Årsstämma
2023-05-25 - Årsstämma
2023-05-19 - X-dag ordinarie utdelning CALTX 0.00 SEK
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-14 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning CALTX 0.00 SEK
2022-05-19 - Årsstämma
2022-05-18 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - Årsstämma
2021-05-13 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning CALTX 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning CALTX 0.00 SEK
2020-06-25 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-03-03 - Extra Bolagsstämma 2020
2020-02-14 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-08 - Kvartalsrapport 2019-Q1
2019-05-08 - Årsstämma
2019-02-08 - X-dag ordinarie utdelning CALTX 0.00 SEK
2019-02-07 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Calliditas Therapeutics är verksamt inom läkemedelsindustrin. Bolaget är specialiserat inom forskning och utveckling av medicinska produkter, särskilt inriktade mot behandling av injur- och leversjukdomar. Exempel på specialistområden inkluderar skivepitelcancer, autoimmun hepatit samt nefropati. Bolaget grundades 2004 och innehar verksamhet på global nivå, med huvudkontor i Stockholm.
2024-08-01 15:00:00

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on August 9 – 10.

The panel, titled “How to be Efficient as a Leader in Academia and Industry,” will focus on the importance of female representation and leadership. On that topic, Aguiar-Lucander notes, “I believe women in the industry have made great strides in terms of leadership positions but there is clearly still significant work to do. The industry remains male-dominated and closed networks still exist. It’s therefore important to shine a light on all of the success that female leaders have achieved and how diversity and a variety of leadership styles continue to successfully drive innovation, growth and profitability. We should publicize and celebrate this positive change whilst improving mentorship and support all of the amazing women in our organizations. If we can do that, I’m hopeful that more women will rise to the top and excel at whatever they set their minds to.”

WIN was founded in 1983 by women in the nephrology field who had a goal of developing and providing mentorship and guidance to all nephrologists and scientists, including those that historically have been under-represented. In alignment with this goal, Aguiar-Lucander will be speaking to her experience in management, the art of building a winning organization as CEO, and the specific impact of the women in leadership at Calliditas.

For more information about this conference, visit the Women in Nephrology website here.

About Calliditas
Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in rare diseases with significant unmet medical needs. Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.

For further information, please contact:

Emma Santos
egsantos@lifescicomms.com